Cethromycin

From Wikipedia, the free encyclopedia

Cethromycin
Systematic (IUPAC) name
(1S,2R,5R,7R,8R,9S,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-Dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
Identifiers
CAS number 205110-48-1
ATC code  ?
PubChem 5282045
Chemical data
Formula C42H59N3O10 
Mol. mass 765.931 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status

Phase III Clinical Trials in US
Routes Oral

Cethromycin (initially known as ABT-773) is a macrolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication.[1] Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.

On April 10, 2008, Advanced Life Sciences announced that, based on a productive meeting with the U.S. Food and Drug Administration (FDA), it plans to submit a New Drug Application (NDA) in the third quarter of 2008 for cethromycin to treat mild-to-moderate community acquired pneumonia.[2]

[edit] References

  1. ^ Cethromycin - Advanced Life Sciences
  2. ^ Cethromycin New Drug Application
v • d • e
Antibacterials for systemic use: macrolides, lincosamides and streptogramins (J01F)
Macrolides
Lincosamides
Streptogramins
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.